Department of Urology, Division of Transplantation, University of Miami Miller School of Medicine, Miami, Florida 33136, USA.
Urology. 2010 Jun;75(6):1335-42. doi: 10.1016/j.urology.2009.10.030. Epub 2009 Dec 29.
To evaluate LRN as treatment for high risk patients. Laparoscopic radical nephrectomy (LRN) is performed for renal tumors not amenable to nephron-sparing treatments. Indications are increasing to include higher risk patients including those with end-stage renal disease (ESRD) necessitating dialysis.
We performed a retrospective analysis of a patient cohort with clinical stage T1 renal tumors undergoing transperitoneal LRN. Parameters examined included patient demographics, medical comorbidities, tumor characteristics, operative outcomes, and complications.
One hundred eighty-nine patients underwent 195 LRN. Sixteen patients (8.5%) had preexistent ESRD requiring dialysis. A higher American Society of Anesthiologists score (P<.05), higher age-adjusted Charlson comorbidity index (P=.003), higher incidence of previous abdominal surgery (P=.012), and higher incidence of hypertension (P=.025) were found for the ESRD group. Mean blood loss was 153.0 and 132.0 mL (P=.71) in the ESRD patients and non-ESRD patients, respectively. A longer stay (P=.02) was noted for ESRD patients. Mean tumor size in the ESRD patients and non-ESRD patients was 2.6 and 4.2 cm (P<.05), respectively. Renal cell carcinoma was the most common pathology in 14 of 20 (70.0%) ESRD patient renal units and 167 of 175 (95.4%) non-ESRD patient renal units (P=.001). Intraoperative and postoperative complication rates were 6.3% and 31.3% respectively for ESRD patients (P=.05), and 8.7% and 21.4% respectively for non-ESRD patients (P=.35). Most postoperative complications were minor.
LRN, for the treatment of renal tumors in ESRD patients requiring dialysis, is feasible and safe with acceptable intraoperative and postoperative complication rates. Patients with ESRD may require longer hospital stay after LRN.
评估 LRN 作为高危患者的治疗方法。腹腔镜根治性肾切除术(LRN)适用于不适于保留肾单位治疗的肾肿瘤。适应证包括越来越多的高危患者,包括需要透析的终末期肾病(ESRD)患者。
我们对接受经腹腔 LRN 的临床 T1 期肾肿瘤患者进行了回顾性分析。检查的参数包括患者人口统计学、合并症、肿瘤特征、手术结果和并发症。
189 例患者行 195 例 LRN。16 例(8.5%)患者患有需要透析的预先存在的 ESRD。ESRD 组的美国麻醉医师协会评分较高(P<.05)、年龄调整后的 Charlson 合并症指数较高(P=.003)、既往腹部手术发生率较高(P=.012)和高血压发生率较高(P=.025)。ESRD 患者和非 ESRD 患者的平均失血量分别为 153.0 和 132.0 mL(P=.71)。ESRD 患者的住院时间较长(P=.02)。ESRD 患者和非 ESRD 患者的平均肿瘤大小分别为 2.6 和 4.2 cm(P<.05)。在 20 例 ESRD 患者的肾脏单位中,14 例(70.0%)为肾细胞癌,在 175 例非 ESRD 患者的肾脏单位中,167 例(95.4%)为肾细胞癌(P=.001)。ESRD 患者的术中并发症发生率和术后并发症发生率分别为 6.3%和 31.3%(P=.05),非 ESRD 患者分别为 8.7%和 21.4%(P=.35)。大多数术后并发症为轻微并发症。
LRN 治疗需要透析的 ESRD 患者的肾肿瘤是可行且安全的,术中及术后并发症发生率可接受。ESRD 患者在 LRN 后可能需要更长的住院时间。